Immune Thrombocytopenia clinical trials at UCSF
1 in progress, 0 open to eligible people
Showing trials for
Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
Sorry, in progress, not accepting new patients
This is a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of <30,000/μL (and no single platelet count >35,000/μL) on two counts at least 5 days apart in the 14 days before…
San Francisco, California and other locations